3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
177
Neoplasm Metastasis
19
Breast Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
17
Neoplasms
17
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Castration-resistant Prostate Cancer
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
Doxorubicin
25
Radiotherapy
16
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Radiation
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
abemaciclib
3
X-Rays
3
Vincristine
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liposarcoma
×
enzalutamide
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled